How to Buy Uipath Stock
Uipath Inc
Uipath is a software infrastructure company located in New York, United States, which is part of the Technology sector, and is traded under the ticker PATH on the NYSE exchange.
Uipath stock last closed at $12.29, down 1.6% from the previous day, and has decreased 26.71% in one year. It has overperformed other stocks in the Software - Infrastructure industry by 0.01 percentage points. Uipath stock is currently +18.51% from its 52-week low of $10.37, and -55.9% from its 52-week high of $27.87.
As of Oct 7, 2024, there are 549.96M shares of PATH outstanding. The market cap of PATH is $6.76B. In the last 24 hours, 6.62M PATH shares were traded.
How to Buy Uipath Stock
Not sure how to invest in Uipath stock? Here's how.
- Figure out where to buy Uipath stock: You need to decide on a stock brokerage, but don't worry - we've analyzed dozens of online stock brokerages and apps to help you decide where to buy Uipath stock.
- Open a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've identified.
- Deposit funds into your brokerage account: Pick your payment method and add your information.
- Evaluate Uipath stock: The Uipath ticker symbol is PATH. Is Uipath stock a good investment? Should you buy shares of PATH? How do PATH's underlying business fundamentals look? Do top analysts think Uipath is a good buy? Why has PATH's stock price moved recently? (Hint: Our stock market analysis tools can help you figure out if PATH is a good stock to buy).
- Place your PATH trade: Decide if you will purchase PATH shares at the current market price or use a limit order to buy PATH stock at a specific price.
- Monitor your PATH position: Create a watchlist to track your position in Uipath shares.
Step 1: Figure out where to buy Uipath stock
You need a brokerage account to access the NYSE market and buy PATH shares.
Our preferred brokerage: eToro
Based on our experience, eToro is the best stock brokerage. Here's why:
- You can invest in stocks with zero commissions: Invest without commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still buy the stock.
- Access to world financial markets: From Technology to Industrials, New York to Hong Kong — you can fill your portfolio with stocks from the globe's leading exchanges.
- Social investing: eToro offers a community with more than 20 million users around the world. Talk to, learn from, and copy the unique crypto portfolios of top investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your purchase of stock by creating an account with eToro now.
Open eToro AccountStep 2: Open a brokerage account
Now that you've picked the right brokerage, you need to fill out some personal information so you are able to invest in PATH today.
How to Start a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal data to create a new trading account.
- Send your info by clicking the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your brokerage account
Now that you've filled out your info on the best app for stock investing, your next step is to transfer the money for your investment:
Check out the video below to see the process of transferring money into your new investment account.
Step 4: Evaluate Uipath stock
Once you have identified the best place to buy Uipath stock, it's absolutely critical to evaluate their stock before you buy, so you can wrap your head around the risk and upside.
Uipath shares at a glance
Uipath Zen Score
WallStreetZen was designed to help part-time investors do better fundamental analysis.
You can see all of the due diligence checks on PATH's stock page.
Is PATH stock undervalued or overvalued?
Analysts use a variety of different financial metrics, analyses, models, and charts to gauge PATH's true value.
Using relative valuations methods:
- PATH could be undervalued based on its P/B ratio of 3.69x, relative to Software - Infrastructure industry P/B ratio of 11.51x
You can do more valuation research on PATH's stock here.
PATH Financial Health Summary
Pros:
- PATH profit margin has gone up from -15.5% to -8.1% in the past year.
- There are more short-term assets than long-term liabilities on the PATH balance sheet.
- PATH's operating cash flow of $333.87M allows it to safely service it's debt of $78.17M.
- There are more short-term assets than short-term liabilities on the PATH balance sheet.
Cons:
- PATH earnings of -$98.24M is not sufficient to cover its interest payments.
- PATH has a relatively high debt to equity ratio of 0.47.
Is it a good time to buy Uipath stock, according to analysts?
Out of 16 Wall Street analysts who track PATH, the consensus analyst rating on PATH is a Hold
Please note that analyst forecasts are not recommendations, nor are they financial advice.
Latest PATH Analyst Forecasts
Michael Turrin, a bottom 15% analyst from Wells Fargo maintains PATH with a hold rating and raises their PATH price target from $14.00 to $15.00, on Sep 6, 2024.
Kirk Materne, a top 14% analyst from Evercore ISI Group maintains PATH with a hold rating and raises their PATH price target from $13.00 to $16.00, on Sep 6, 2024.
Keith Bachman, a top 2% analyst from BMO Capital maintains PATH with a hold rating and raises their PATH price target from $14.00 to $15.00, on Sep 6, 2024.
Brad Sills, a top 5% analyst from Bank of America maintains PATH with a hold rating and raises their PATH price target from $16.00 to $18.00, on Sep 6, 2024.
Frederick Havemeyer, a bottom 7% analyst from Macquarie downgrades PATH to a hold rating and lowers their PATH price target from $29.00 to $12.00, on Jun 3, 2024.
Macquarie's Frederick Havemeyer downgraded their rating on Uipath (NYSE: PATH) from Buy to Hold on 2024/06/03. The analyst also lowered their price target by 58.6% from $29 to $12.
Uipath reported its Q1 2025 earnings on 2024/05/29.
Havemeyer summarized the results as "in line with expectations," but noted that management cut its FY 2025 guidance because of "headwinds impacting large, multi-year deals."
Looking ahead, the analyst cautioned that Macquarie "sees no clear near-term path for Uipath to re-accelerate growth."
Earnings Report
For Q1 2025, Uipath reported:
- EPS of $0.13, which beat the Zacks Consensus Estimate and Q1 2023, both $0.11, by 18.2%.
- Revenue of $335.11M, which beat the Zacks Consensus Estimate by 0.68% and, by 15.7%, Q1 2023's $289.59M.
- ARR (Annual Recurring Revenue) of $1.51B, up 21% Y/Y.
- Operating income of $50.4M, up from Q1 2023's $48.2M.
Management guided:
For Q2 2025:
- Revenue of $300M to $305M.
- ARR of $1.543B to $1.548B.
- Operating income to break even.
For FY 2025:
- Revenue of $1.405B to $1.41B.
- ARR of $1.66B to $1.665B.
- Operating income of $145M.
Founder & Chief Innovation Officer Daniel Dines commented: “We are pleased to report that ARR surpassed $1.5B in Q1 2025, a testament to our market-leading Business Automation Platform and the strategic role automation plays in digital transformation.
“We believe the foundation of our business remains strong and we are optimistic about our ability to drive growth and profitability through improved execution, customer centricity, and continued innovation.”
CFO Ashim Gupta added: “During Q1 we saw increased deal scrutiny and lengthening sales cycles for large multi-year deals.
"We have considered these factors, the current macroeconomic environment, and our leadership transition in our updated guidance for the remainder of the year.
“While our revenue and operating margin guidance are impacted by contract timing and duration, we have confidence in our ability to generate durable ARR growth at scale, and meaningful non-GAAP adjusted free cash flow.”
You can dive deeper into what analysts are saying on the Uipath stock forecast page.
PATH Trading Indicators
PATH Performance Numbers
Last year, PATH revenue was $1.38B. In the last three year, PATH's revenue has gone up by 95.69% per year. This was faster than the Software - Infrastructure industry average of 17.64%.
You can research PATH's earnings and revenue performance here.
What are PATH insiders up to?
Over the past year, executives and large shareholders at PATH have sold more shares than they have bought.
Ashim Gupta, COO CFO of PATH, was the latest PATH insider to sell. They sold $572,816.28 worth of PATH stock on Oct 3, 2024.
Research more about who owns PATH stock here.
Does PATH stock generate passive income?
No, Uipath doesn't provide an income stream by paying out dividends.
Get opinions from other investors
One of the primary reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to see what other investors have to say.
Step 5: Place your PATH trade
There are two primary options:
- Market order: A market order is an order to buy or sell a security at the best possible price.
Market orders are generally the easiest way to buy. - Limit order: A limit order enables you to buy or sell a security at a specific price (or better).
If you want to be sure you're buying or selling at a given price limit, place a limit order.
Hit the Open button and your broker will execute your order.
If you want more info about buying stocks on eToro, watch the how to video below:
Step 6: Monitor your PATH position
Now that you own some shares in PATH, you'll want to keep up with your investment.
Add PATH to a watchlist to get alerted to the latest events about your PATH stock.
PATH Feed
How to Buy Stock in Uipath
To reiterate, here are the 6 steps to buy Uipath stock:
- Figure out where to buy Uipath stock
- Open a brokerage account
- Deposit funds into your brokerage account
- Evaluate Uipath stock
- Place your PATH trade
- Monitor your PATH position
If you are looking for a online brokerage, eToro is our favorite venue.
Get Started with eToro TodayIf you would like to get notifications regarding your investment in Uipath, create your watchlist below.
Other Articles You May Like
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.